PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (Nasdaq: BJCT), the worldwide leader in developing and supplying needle-free injection therapy (NFIT) systems, today announced it has entered into a convertible note financing agreement with Signet Healthcare Partners for $600,000. Bioject has raised $1.215 million in convertible debt since November 20, 2007. The convertible notes bear interest at 8% per annum and become due on May 15, 2009, if not automatically or voluntarily converted into shares of Bioject stock prior to that date.
